



FINAL PROGRAMME

THURSDAY 9 APRIL 2015

- | | |
|----------------------|---|
| 08.30 - 12.30 | THE NATURE OF SE: EXPERIMENTAL ASPECTS

Chair: D. Kullmann (United Kingdom) and J. Kapur (USA) |
| 08.30 - 08.40 | Welcome and introduction
S. Shorvon (United Kingdom) and E. Trinka (Austria) |
| 08.40 - 09.20 | Is hypoxia important in status epilepticus?
G. Biagini (Italy) |
| 09.20 - 10.00 | Structural and functional changes in astrocytes following SE
K. Wilcox (USA) |
| 10.00 – 10.30 | Coffee break

Chair: D. Lowenstein (USA) and A. Rossetti (Switzerland) |
| 10.30 - 11.10 | What are the physiological bases of GPEDs and other EEG patterns in status epilepticus?
M. van Putten (The Netherlands) |
| 11.10 - 11.50 | Is spreading depolarization important in status epilepticus?
J. Dreier (Germany) |
| 11.50 - 12.30 | What does burst suppression really mean?
F. Amzica (Canada) |
| 12.30 - 14.00 | POSTERS AND LUNCH |
| 14.00 - 18.00 | THE NATURE OF SE: CLINICAL ASPECTS

Chair: H. Cross (United Kingdom) and R. Guerrini (Italy) |
| 14.00 - 14.40 | Genetic defects of mitochondrial pathways leading to status epileptics
S. Rahman (United Kingdom) |




- 14.40 - 15.20** **Status epilepticus, inflammation and blood brain barrier disruption**
J. Gorter (The Netherlands)
- 15.20 - 16.00** **P2X receptors as a link between hyperexcitability and neuroinflammation in status epilepticus**
D. Henshall (Ireland)
- 16.00 - 16.40** **Coffee break**

Chair: N. Bharucha (India) and C. Westerlain (USA)
- 16.40 - 17.20** **Status epilepticus as a phenotype of genetic mutations**
S. Shorvon (United Kingdom)
- 17.20 - 18.00** **Predicting the outcome of status epilepticus**
M. Leitinger (Austria)
- 18.00 - 18.45** **Expert Panel Discussion:**
The experimental and clinical nature of status epilepticus
Chair: E. Trinka (Austria)
C. Wasterlain (USA), D. Lowenstein (USA), J. Kapur (USA),
A. Rossetti (Switzerland), R. Guerrini (Italy)
- 20.00 - 23.00** **RECEPTION AND GALA DINNER (Royal College of Physicians)**

FRIDAY 10 APRIL 2015

- 08.30 - 12.30** **CLINICAL ASPECTS OF STATUS EPILEPTICUS**

Chair: M. Koepp (United Kingdom) and D. Lowenstein (USA)
- 08.30 - 09.10** **The nature of neonatal SE**
D. Dlugos (USA)
- 09.10 - 09.50** **Drug induced status epilepticus**
H. Cock (United Kingdom)
- 09.50 - 10.30** **Can anaesthetic treatment worsen outcome in status epilepticus?**
R. Sutter (Switzerland)



10.30 - 11.10	Coffee break Chair: T. Bleck (USA) and R. Guerrini (Italy)
11.10 - 11.50	Systemic complications of status epilepticus S. Hocker (USA)
11.50 -12.30	Audit of treatment in refractory status epilepticus M. Ferlisi (Italy)
12.30 -14.00	POSTERS AND LUNCH
14.00 - 14.50	Town Hall Meeting Chair: S. Shorvon (United Kingdom) and E. Trinka (Austria) How can the international community organise itself to improve outcomes in status epilepticus ? (For the development of a green paper on status epilepticus)
14.50 - 15.30	Coffee break
15.30 - 17.30	ELECTROGRAPHIC SE Chair: R. Pressler (United Kingdom) and A. Rossetti (Switzerland)
15.30 - 16.10	Electrographic status epilepticus in critically ill children: Epidemiology and outcome N. Abend (USA)
16.10 - 16.50	Outcome of electrographic status epilepticus T. Loddenkemper (USA)
16.50 - 17.30	Which EEG Patterns in Coma are nonconvulsive status epilepticus? E. Trinka (Austria)
17:30 - 18.10	Debate Chair: S. Shorvon (United Kingdom) Motion: Should PEDs (and similar EEG patterns) in post-anoxic status epilepticus be treated ? Pro: L. Hirsch (USA) Contra: P. Kaplan (USA)



SATURDAY 11 APRIL 2015

09.00 - 14.20	NOVEL ASPECTS IN THE DRUG TREATMENT OF SE Chair: E. Perucca (Italy) and C. Wasterlain (USA)
09.00 - 09.40	New therapies introduced into clinical practice E. Trinka (Austria)
09.40 - 10.10	Intranasal therapies of acute seizures Reetta Kälviäinen (Finland)
10.10 - 10.40	Intramuscular and rectal therapies of acute seizures I. Leppik (USA)
10.40 - 11.10	Lacosamide A. Husain (USA)
11.10 - 11.40	Coffee break Chair: J. Kapur (USA) and T. Bleck (USA)
11.40 - 12.20	New experimental therapies in pre-clinical development M. Walker (United Kingdom)
12.20 - 12.50	Single v. combinational therapies in SE W. Löscher (Germany)
12.50 - 13.20	Neurosteroids M. Rogawski (USA)
13.20 - 13.50	SPD and valnoctamide M. Bialer (Israel)
13.50 - 14.20	tbc
14.20	END